NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Impact of HIV-1 and Aging on Mucosal Vaccine Responses

Active Not RecruitingEARLY_Phase 1

Sponsor: VA Eastern Colorado Health Care System

Conditions: HIV-1-infection, Human Immunodeficiency Virus, HIV/AIDS, HIV Infections

Interventions: Prevnar-13

Countries: United States

The purpose of this study is to learn more about both HIV-1 infection and advancing age, and their association with increased risk of serious infection and impaired response to the Prevnar 13 vaccine.

Eligibility overview

Sex: ALL

Age: 21 Years to 75 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Veterans only (accessibility to non-veterans pending)
* Age 21-45 or 55-75 Years Old
* Have not received pneumococcal vaccine Prevnar PCV-13
* Able to attend 2-3 study visits over 1 month

HIV+:

-Undetectable Viral load

HIV negative controls:

-no history or risks for HIV infection

Exclusion Criteria:

* Spleen removed
* Chronic Kidney disease (creatinine ≥ 2.0 mg/dL)
* Active liver disease
* Currently taking: Corticosteroids (prednisone, medrol, etc), Chemotherapy, Immunosuppressive medication (cyclosporine, methotrexate, azathioprine, infliximab, adalimumab, rituximab, etanercept, etc), or illicit drugs (methamphetamine, cocaine, crack, or heroin)

Locations (1)

Aurora, Colorado, United States